For healthcare professionals only
GPnotebook

This promotional website has been developed, organised and funded by Boehringer Ingelheim.​

Prescribing information for Great Britain, Northern Ireland and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Learning modules

  • Chapter 1

Hypoglycaemia and type 2 diabetes

  • Click here to access the module
  • Chapter 2

Renal function decline and type 2 diabetes

  • Click here to access the module
  • Chapter 3

Type 2 diabetes in a frail older person

  • Click here to access the module
  • Webinar

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

VIEW HERE
  • VIRTUAL WEBINARS
Initiated and funded by
Boehringer Ingelheim
PC-GB-110175 V2 | December 2024

Prescribing information for Great Britain, Northern Ireland and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-108643 V6 | December 2024

This website is for healthcare professionals in the United Kingdom and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in the United Kingdom or the Republic of Ireland by clicking below.

I am
I am not
Prescribing information for the United Kingdom and the Republic of Ireland 

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel